Immunology companies study and manipulate the immune system to develop therapies, diagnostics and research tools. The field plays a central role in areas such as cancer, infectious disease, autoimmune disorders and vaccine development.
This category includes companies working on:
Browse 182 UK immunology companies below.
GPCR-targeted small molecule drugs for rare and inflammatory disease
Trio Medicines is a small pharmaceutical company developing small molecule therapeutics targeting G-protein coupled receptors for diseases with unmet clinical need. Its pipeline includes gastrin/CCK2 receptor antagonists for gastric neuroendocrine tumours, a selective β2-adrenoceptor antagonist, and a formyl peptide…
Antibody therapeutics targeting glycosphingolipid inflammation
Protalea Bio is a biotech company developing first-in-class therapeutic antibodies to prevent progression from precancerous states to active blood cancers including multiple myeloma and B-cell lymphoma. The company's approach targets glycosphingolipid-related inflammation before disease onset, building on over fifteen…
Microfluidic avidity platform for preclinical cell therapy validation
Avigen is a contract research organisation providing preclinical validation services for cellular immunotherapies using a proprietary microfluidic platform. The platform measures cellular avidity, the total binding strength between immune and cancer cells, at high throughput using fluid shear stress, enabling…
Blood glycomic biomarkers for chronic inflammatory disease detection and monitoring
Avenna is a biotechnology company developing blood-based glycomic biomarkers for chronic inflammatory diseases. Its tests analyse the sugar structures attached to blood proteins to measure chronic inflammation separately from short-term acute inflammation, supporting early detection, disease monitoring and…
Antibody therapies targeting severe autoimmune diseases
argenx UK Ltd is the UK commercial subsidiary of argenx SE, a global immunology company developing antibody-based therapies for severe autoimmune diseases. The company markets VYVGART (efgartigimod), the first approved FcRn blocker in the UK, indicated for generalised myasthenia gravis and chronic inflammatory…
Peptide immunotherapies for the treatment of food allergy
Aravax is a clinical-stage biotechnology company developing next-generation specific immunotherapies for food allergy. Its lead candidate, PVX108, is a synthetic peptide-based therapy designed to desensitise peanut-allergic patients by targeting the T cells that drive allergic responses, without triggering acute…
Global biopharmaceutical company developing therapies for serious diseases
AbbVie is a global research-based biopharmaceutical company focused on the discovery, development and commercialisation of medicines across immunology, oncology, neuroscience and aesthetics. Its portfolio includes treatments for autoimmune diseases, haematological cancers, neurological conditions and women's health.…
Antigenic immunomodulation therapies targeting autoimmune disease
Phaim Pharma is a biotech company developing disease-modifying therapeutics for autoimmune conditions using its proprietary platform. The platform is designed to reset the immune system by reintroducing disease-specific antigenic epitopes, suppressing the autoaggressive T cell responses that underlie conditions such…
Antibody discovery biotech targeting GPCRs in inflammatory disease
DJS Antibodies is a biotechnology company developing monoclonal antibody therapeutics against G protein-coupled receptors and other previously intractable disease targets. Its proprietary antibody discovery platform enables the generation of first-in-class antibodies against transmembrane proteins that have…
Immunological reagents, assay services and target-binding proteins for immune research
ProImmune is a provider of immunological reagents and assay services supporting research into adaptive immune responses. The company offers assay services to help researchers understand immune responses to vaccines and therapeutics, using ELISpot and flow cytometry techniques, alongside recombinant target-binding…
Clinical-stage bispecific antibody therapies for cancer and blood disease
NovalGen is a clinical-stage biotechnology company developing multi-specific biologics for oncology, haematological malignancies, and autoimmune diseases. Its proprietary platform embeds a feedback mechanism into therapeutic biologics that deactivates the drug in response to excessive immune activation, aiming to…
UK affiliate of global innovative medicines company Novartis AG
Novartis Pharmaceuticals UK Limited is the UK commercial and medical affiliate of Novartis AG, the Swiss-headquartered global pharmaceutical company. Headquartered at White City Place in London, the UK operation employs approximately 1,300 people and focuses on commercialisation, medical affairs, regulatory…
Synthetic T cell-priming vaccines and immunotherapies for infectious disease
Gylden Pharma is a clinical-stage biotechnology company developing 100% synthetic T cell-priming vaccines and immunotherapies. Its nanoparticle platform delivers synthetic peptides that stimulate cellular immune responses against intracellular pathogens, providing strain-agnostic protection without cold-chain…
Anti-inflammatory drugs for neurodegenerative disease
Sitala Bio is a Cambridge-based biotech developing small molecule drugs that target chronic neuroinflammation in conditions such as Parkinson's and Alzheimer's disease. The company's approach focuses on blocking microglial dysfunction to restore toxin clearance in the brain. Founded by NLRP3 inflammasome expert Matt…
Biological raw materials and IVD test platforms for diagnostics
BBI Solutions is a global manufacturer of biological raw materials and finished test platforms for the in-vitro diagnostics market. Products include antibodies, antigens, enzymes, gold nanoparticles, and serum and plasma materials used across lateral flow, ELISA, biosensor, and clinical chemistry applications. The…
Recombinant Fc receptors for antibody research and development
Gamma Proteins is a Durham-based reagent company supplying recombinant Fc receptors for antibody research and biopharmaceutical development. Its catalogue includes Fc gamma receptors and neonatal Fc receptor (FcRn), with human and selected animal proteins offered in unconjugated and biotinylated formats. The proteins…
Oncolytic virus immunotherapies engineered to destroy solid tumours
Bioarchitech is a preclinical-stage biotechnology company developing oncolytic virus-based immunotherapies for the treatment of common solid tumours. The company engineers vaccinia virus to encode antibody-like immunotherapy molecules within the viral genome, enabling localised delivery of immune-activating payloads…
Intranasal anti-CD3 immunotherapy for neuroinflammatory diseases
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapies for neurological and inflammatory diseases. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to modulate T-cell activity through nasal administration. The 48-patient…
Macrophage-targeted therapeutics for oncology, neurological and fibrotic diseases
Macomics is a University of Edinburgh spin-out developing macrophage-targeted medicines across oncology, neurodegenerative, inflammatory and fibrotic diseases. Its ENIGMAC drug discovery platform combines human macrophage and microglia models derived from induced pluripotent stem cells, gene editing and…
Antigen modulation therapies for cancer and autoimmune disease
Grey Wolf Therapeutics is a clinical-stage biotechnology company developing small molecule inhibitors of endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2) to modulate antigen presentation on cell surfaces. In oncology, this approach enhances tumour visibility to the immune system; in autoimmunity, it aims to…